<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-24812" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Mebendazole</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Thakur</surname>
            <given-names>Rahul K.</given-names>
          </name>
          <aff>Roswell Park Comprehensive Cancer Center/ State University of Buffalo</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Shivani P.</given-names>
          </name>
          <aff>Ahmedabad University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Rahul Thakur declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Shivani Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>15</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-24812.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Mebendazole is a medication used in the treatment of parasitic infection. This activity reviews the indications, contraindications, activity, adverse events, and other key elements of mebendazole therapy in the clinical setting related to the essential points needed by members of an interprofessional team managing the care of patients with parasitic infection and related conditions and sequelae.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action of mebendazole.</p></list-item><list-item><p>Describe the potential adverse effects of mebendazole.</p></list-item><list-item><p>SUmmarize dose-response monitoring for patients on mebendazole therapy.</p></list-item><list-item><p>Review interprofessional team strategies for improving care coordination and communication to advance mebendazole and improve outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=24812&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=24812">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-24812.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Mebendazole is a typical, broad-spectrum benzimidazole used for more than 40 years in humans to treat various parasitic infestations.&#x000a0;It has FDA approval for the treatment&#x000a0;of patients greater than two years of age with gastrointestinal infections caused by <italic toggle="yes">Necator</italic>&#x000a0;<italic toggle="yes">americanus or&#x000a0;<italic toggle="yes">Ancylostoma</italic>&#x000a0;<italic toggle="yes">duodenale</italic>&#x000a0;</italic>(hookworms),&#x000a0; <italic toggle="yes">Ascaris&#x000a0;lumbricoides&#x000a0;</italic>(roundworms),&#x000a0; <italic toggle="yes">Enterobius vermicularis</italic>&#x000a0;(pinworms), and&#x000a0;<italic toggle="yes">Trichuris trichiura</italic>&#x000a0;(whipworms)&#x000a0;in single or mixed infections.<xref ref-type="bibr" rid="article-24812.r1">[1]</xref></p>
        <p>It also has several off-label uses for adult intestinal nematode infection caused by<bold>&#x000a0;c</bold>apillariasis; echinococcosis, cystic (<italic toggle="yes">Echinococcus granulosus</italic>); toxocariasis; trichinellosis (<italic toggle="yes">Trichinella spiralis</italic>); trichostrongyliasis.<xref ref-type="bibr" rid="article-24812.r2">[2]</xref></p>
        <p>Mebendazole is a new purposed drug in oncology with a focus on cells resistant to approved therapies. Mebendazole exhibits cytotoxic activity, which synergizes with ionizing radiations and different chemotherapeutic agents and stimulating an antitumoral immune response.<xref ref-type="bibr" rid="article-24812.r3">[3]</xref>&#x000a0;Recent studies have shown mebendazole is also a better replacement for vincristine to treat brain tumors&#x000a0;in animal models.<xref ref-type="bibr" rid="article-24812.r4">[4]</xref></p>
      </sec>
      <sec id="article-24812.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Mebendazole acts by inhibiting the production of microtubules via binding to colchicine&#x000a0;binding-site of&#x000a0;&#x003b2;-tubulin and thereby blocking polymerization of&#x000a0;tubulin&#x000a0;dimers in the intestinal cells of parasites.<xref ref-type="bibr" rid="article-24812.r5">[5]</xref>&#x000a0;Consequently, glucose uptake and the digestive and reproductive capacities of parasites are interrupted,&#x000a0;resulting in immobilization, hindrance of egg production, and death of the helminth. Mebendazole is poorly absorbed in the digestive tract&#x000a0;making it&#x000a0;an effective medication for managing intestinal helminthic infections with very few&#x000a0;side effects.</p>
        <p>There is a possibility for the development of resistance to mebendazole. The mechanism of resistance to benzimidazole is most likely due to changes in &#x003b2;-tubulin protein, which decreases the binding of mebendazole to &#x003b2;-tubulin.<xref ref-type="bibr" rid="article-24812.r6">[6]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-24812.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Mebendazole is administered orally without regard to meals.&#x000a0;The patient&#x000a0;must chew&#x000a0;the tablet&#x000a0;completely before swallowing. For patients who have difficulty taking the tablet, it can be placed in a spoon and mixed with 2&#x000a0;to 3 ml of drinking water using a dosing syringe. The pill absorbs the water and turns into a soft mass with semi-solid consistency, which is easily swallowable.</p>
        <p>Dosing of mebendazole for common FDA indications are listed below:</p>
        <list list-type="bullet">
          <list-item>
            <p>Roundworm (<italic toggle="yes">Ascaris lumbricoides)</italic>: 100 mg twice daily (morning and night) for three consecutive days.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Hookworm (<italic toggle="yes">Ancylostoma duodenale):</italic>&#x000a0;100 mg twice daily (morning and night) for three consecutive days</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Whipworm (<italic toggle="yes">Trichuris trichiura</italic>): 100 mg twice daily (morning and night) for three consecutive days</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Pinworm (<italic toggle="yes">Enterobius vermicularis</italic>): 100-mg single oral dose</p>
          </list-item>
        </list>
        <p>If the patient does not achieve satisfactory results after three weeks of medication, then a second course of therapy is recommended. Dosing of mebendazole for common non-FDA approved indications are listed below:</p>
        <list list-type="bullet">
          <list-item>
            <p>Capillariasis Infection: 200 mg to be administered orally twice daily for 20 days<xref ref-type="bibr" rid="article-24812.r1">[1]</xref><xref ref-type="bibr" rid="article-24812.r7">[7]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Cestodes Infection: 300 mg to be administered orally twice daily for 3&#x000a0;to 6 days<xref ref-type="bibr" rid="article-24812.r8">[8]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Filariasis: 300 mg to be taken orally daily for 28&#x000a0;to 45 days<xref ref-type="bibr" rid="article-24812.r9">[9]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <p>Less than ten (10%) of the drug undergoes systemic absorption after oral ingestion, and this portion undergoes metabolism rapidly by hepatic enzymes. Plasma levels may also decrease by carbamazepine or phenytoin or any CYP450 inducer. Cimetidine does not appreciably raise serum mebendazole, which is consistent with its poor systemic absorption.<xref ref-type="bibr" rid="article-24812.r10">[10]</xref>&#x000a0;Mebendazole is largely metabolized primarily by the liver. Higher plasma levels of mebendazole will occur in patients with impaired liver function or decreased biliary excretion. The half-life of mebendazole is around 3&#x000a0;to 6 hours after oral administration. Mebendazole excretion occurs mostly in bile or urine.</p>
      </sec>
      <sec id="article-24812.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>The most common adverse effects accompanying mebendazole use are loss of appetite, abdominal pain, diarrhea, flatulence, nausea, vomiting, headache, tinnitus, and elevated liver enzymes.<xref ref-type="bibr" rid="article-24812.r11">[11]</xref>&#x000a0;A small percentage of patients may experience convulsions, and some may have hypersensitivity reactions such as rash, urticaria, and angioedema.&#x000a0;</p>
        <p>Mebendazole toxicity is usually limited to gastrointestinal irritation, but there are reports of other serious side effects, including neutropenia (including agranulocytosis) and/or thrombocytopenia, particularly in patients who have received higher dosages or&#x000a0;had a more prolonged treatment course than usually recommended.<xref ref-type="bibr" rid="article-24812.r12">[12]</xref></p>
      </sec>
      <sec id="article-24812.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Mebendazole is contraindicated in a person with documented hypersensitivity to mebendazole or&#x000a0;the excipients used in the dose form. Mebendazole is contraindicated in children below the age of 1 year for the mass treatment of single or mixed gastrointestinal infestations because of the risk of convulsion, which has been reported during postmarketing use. There is limited studied in children below the age of 2 years. Clinicians&#x000a0;must&#x000a0;use the drug with attention in patients with hepatic disease or dysfunction&#x000a0;since the liver metabolizes the drug by the CYP450 system.&#x000a0;Also, it should be used carefully in a&#x000a0;patient with biliary obstruction as the medication gets&#x000a0;extensively&#x000a0;expelled via the biliary system. Avoid concomitant use&#x000a0;of mebendazole and metronidazole as there is a higher risk of&#x000a0;Stevens-Johnson syndrome/toxic epidermal necrolysis.<xref ref-type="bibr" rid="article-24812.r13">[13]</xref></p>
        <p>The FDA classified mebendazole as a category C drug, which states either studies in animals have shown adverse outcomes on the fetus, and there are no available verified studies in women. In recent studies, reports&#x000a0;about first-trimester exposure to mebendazole are limited; however, researchers have not observed an increased incidence of congenital defects while used during the second or third trimester.<xref ref-type="bibr" rid="article-24812.r14">[14]</xref><xref ref-type="bibr" rid="article-24812.r15">[15]</xref>&#x000a0;Drugs should only be an option if the likely advantage justifies the possible risk to the fetus.</p>
        <p>Mebendazole is present in breast milk.&#x000a0;In a limited case series report using mebendazole&#x000a0;during lactation, no adverse outcomes associated with the drug occurred in nursing infants.<xref ref-type="bibr" rid="article-24812.r16">[16]</xref>&#x000a0;Mebendazole is considered&#x000a0;compatible&#x000a0;during&#x000a0;breastfeeding with the latest studies.</p>
      </sec>
      <sec id="article-24812.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Mebendazole efficacy is observable from improvement in symptoms of helminthic infections. Periodic assessment of hematopoietic and hepatic functions is advisable during prolonged therapy.&#x000a0;There have been reports of neutropenia and agranulocytosis with mebendazole use at higher doses and&#x000a0;with more prolonged durations of treatment, as in helminth infections. Elderly patients and patients with comorbid conditions like liver impairment and/or end-stage renal disease require close monitoring. It is also advisable to check for helminth ova in feces within 3&#x000a0;to 4 weeks following the initial therapy of mebendazole.</p>
      </sec>
      <sec id="article-24812.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>In the state of overdose, gastrointestinal&#x000a0;symptoms&#x000a0;(e.g., nausea, diarrhea, vomiting, and abdominal pain)&#x000a0;may&#x000a0;occur. Severe toxicity is not&#x000a0;typically an issue.&#x000a0;In instances of toxicity, induce vomiting and purging using activated charcoal if recent ingestion has occurred, and only if the patient can protect their airway. There is no specific antidote for mebendazole overdose.<xref ref-type="bibr" rid="article-24812.r17">[17]</xref>&#x000a0;Treatment is generally supportive.&#x000a0;Use&#x000a0;fluids and electrolytes in symptomatic patients who develop significant diarrhea and/or vomiting.</p>
      </sec>
      <sec id="article-24812.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Over 1 billion people living&#x000a0;on this planet are yearly affected by the parasitic disease. This condition mainly affects poor people, which leads to an enfeebling disability, and frequently ostracism. Healthcare professionals should focus on massive drug administration in the community to tackle this global burden. An interprofessional team approach&#x000a0;is necessary to improve the health status&#x000a0;of patients suffering from these diseases.&#x000a0;Therefore, the healthcare specialist team approach consisting of pharmacists, nurses, and clinicians needs to collaborate for better outcomes. Long term community program needs to be executed in the endemic regions for a favorable outcome. Mebendazole is one of the&#x000a0;most commonly&#x000a0;used antihelminthic&#x000a0;drugs. It is available throughout the globe because of its low price and limited toxicity profile. There is an increasing incidence of treatment failure in treating hookworm infections with mebendazole. So, there is a huge&#x000a0;challenge for exploring new treatment modalities in managing neglected tropical diseases.<xref ref-type="bibr" rid="article-24812.r18">[18]</xref></p>
        <p>This drug is tolerated well&#x000a0;most of the time with only a few adverse reactions; however, mebendazole&#x000a0;must not be used without practitioner monitoring or permission due to the risk of severe adverse reactions&#x000a0;like pancytopenia; this work&#x000a0;also requires an interprofessional team, coordinating between the prescribing clinician, nursing staff, and the pharmacist. [Level 3]</p>
        <p>Pharmacists&#x000a0;should be&#x000a0;associated with the supervision of a patient taking mebendazole as they help create a proper formulation for the patient. Mebendazole may be confused with metronidazole, so it requires a careful check before dispensing the drug&#x000a0;to the patient.&#x000a0;The&#x000a0;interprofessional coordination of the team will provide&#x000a0;the best possible care to the patients while treating with this drug. [Level 5]</p>
      </sec>
      <sec id="article-24812.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=24812&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=24812">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/24812/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=24812">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-24812.s11">
        <title>References</title>
        <ref id="article-24812.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Keystone</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Murdoch</surname>
                <given-names>JK</given-names>
              </name>
            </person-group>
            <article-title>Mebendazole.</article-title>
            <source>Ann Intern Med</source>
            <year>1979</year>
            <month>Oct</month>
            <volume>91</volume>
            <issue>4</issue>
            <fpage>582</fpage>
            <page-range>582-6</page-range>
            <pub-id pub-id-type="pmid">484964</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24812.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bekhti</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Mebendazole in toxocariasis.</article-title>
            <source>Ann Intern Med</source>
            <year>1984</year>
            <month>Mar</month>
            <volume>100</volume>
            <issue>3</issue>
            <fpage>463</fpage>
            <pub-id pub-id-type="pmid">6696379</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24812.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Guerini</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Triggiani</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Maddalo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bon&#x000f9;</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Frassine</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Baiguini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Alghisi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tomasini</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Borghetti</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pasinetti</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Bresciani</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Magrini</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Buglione</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Mebendazole as a Candidate for Drug Repurposing in Oncology: An Extensive Review of Current Literature.</article-title>
            <source>Cancers (Basel)</source>
            <year>2019</year>
            <month>Aug</month>
            <day>31</day>
            <volume>11</volume>
            <issue>9</issue>
            <pub-id pub-id-type="pmid">31480477</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24812.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>De Witt</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gamble</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hanson</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Markowitz</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Powell</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Al Dimassi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Atlas</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Boockvar</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ruggieri</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Symons</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Repurposing Mebendazole as a Replacement for Vincristine for the Treatment of Brain Tumors.</article-title>
            <source>Mol Med</source>
            <year>2017</year>
            <month>Apr</month>
            <volume>23</volume>
            <fpage>50</fpage>
            <page-range>50-56</page-range>
            <pub-id pub-id-type="pmid">28386621</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24812.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lacey</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Mode of action of benzimidazoles.</article-title>
            <source>Parasitol Today</source>
            <year>1990</year>
            <month>Apr</month>
            <volume>6</volume>
            <issue>4</issue>
            <fpage>112</fpage>
            <page-range>112-5</page-range>
            <pub-id pub-id-type="pmid">15463312</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24812.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lacey</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>The role of the cytoskeletal protein, tubulin, in the mode of action and mechanism of drug resistance to benzimidazoles.</article-title>
            <source>Int J Parasitol</source>
            <year>1988</year>
            <month>Nov</month>
            <volume>18</volume>
            <issue>7</issue>
            <fpage>885</fpage>
            <page-range>885-936</page-range>
            <pub-id pub-id-type="pmid">3066771</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24812.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <article-title>Drugs for parasitic infections.</article-title>
            <source>Med Lett Drugs Ther</source>
            <year>1992</year>
            <month>Mar</month>
            <day>06</day>
            <volume>34</volume>
            <issue>865</issue>
            <fpage>17</fpage>
            <page-range>17-26</page-range>
            <pub-id pub-id-type="pmid">1567506</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24812.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chavarria</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Villarejos</surname>
                <given-names>VM</given-names>
              </name>
              <name>
                <surname>Zeled&#x000f3;n</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Mebendazole in the treatment of taeniasis solium and taeniasis saginata.</article-title>
            <source>Am J Trop Med Hyg</source>
            <year>1977</year>
            <month>Jan</month>
            <volume>26</volume>
            <issue>1</issue>
            <fpage>118</fpage>
            <page-range>118-20</page-range>
            <pub-id pub-id-type="pmid">842772</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24812.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Van Hoegaerden</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ivanoff</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Flocard</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Salle</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chabaud</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>The use of mebendazole in the treatment of filariases due to Loa loa and Mansonella perstans.</article-title>
            <source>Ann Trop Med Parasitol</source>
            <year>1987</year>
            <month>Jun</month>
            <volume>81</volume>
            <issue>3</issue>
            <fpage>275</fpage>
            <page-range>275-82</page-range>
            <pub-id pub-id-type="pmid">3478004</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24812.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Luder</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Siffert</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Witassek</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Meister</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Bircher</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Treatment of hydatid disease with high oral doses of mebendazole. Long-term follow-up of plasma mebendazole levels and drug interactions.</article-title>
            <source>Eur J Clin Pharmacol</source>
            <year>1986</year>
            <volume>31</volume>
            <issue>4</issue>
            <fpage>443</fpage>
            <page-range>443-8</page-range>
            <pub-id pub-id-type="pmid">3816925</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24812.r11">
          <label>11</label>
          <element-citation publication-type="book">
            <chapter-title>Mebendazole</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2021</year>
            <month>9</month>
            <day>18</day>
            <pub-id pub-id-type="pmid">31643221</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24812.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wilson</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Rausch</surname>
                <given-names>RL</given-names>
              </name>
            </person-group>
            <article-title>Mebendazole and alveolar hydatid disease.</article-title>
            <source>Ann Trop Med Parasitol</source>
            <year>1982</year>
            <month>Apr</month>
            <volume>76</volume>
            <issue>2</issue>
            <fpage>165</fpage>
            <page-range>165-73</page-range>
            <pub-id pub-id-type="pmid">7092370</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24812.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>KT</given-names>
              </name>
              <name>
                <surname>Twu</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>RS</given-names>
              </name>
            </person-group>
            <article-title>Outbreak of Stevens-Johnson syndrome/toxic epidermal necrolysis associated with mebendazole and metronidazole use among Filipino laborers in Taiwan.</article-title>
            <source>Am J Public Health</source>
            <year>2003</year>
            <month>Mar</month>
            <volume>93</volume>
            <issue>3</issue>
            <fpage>489</fpage>
            <page-range>489-92</page-range>
            <pub-id pub-id-type="pmid">12604501</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24812.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gyorkos</surname>
                <given-names>TW</given-names>
              </name>
              <name>
                <surname>St-Denis</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Systematic review of exposure to albendazole or mebendazole during pregnancy and effects on maternal and child outcomes, with particular reference to exposure in the first trimester.</article-title>
            <source>Int J Parasitol</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>49</volume>
            <issue>7</issue>
            <fpage>541</fpage>
            <page-range>541-554</page-range>
            <pub-id pub-id-type="pmid">31071321</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24812.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Akpan</surname>
                <given-names>UB</given-names>
              </name>
              <name>
                <surname>Asibong</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Okpara</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Monjok</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Etuk</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Antenatal Deworming and Materno-Perinatal Outcomes in Calabar, Nigeria.</article-title>
            <source>Open Access Maced J Med Sci</source>
            <year>2018</year>
            <month>May</month>
            <day>20</day>
            <volume>6</volume>
            <issue>5</issue>
            <fpage>901</fpage>
            <page-range>901-907</page-range>
            <pub-id pub-id-type="pmid">29875869</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24812.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Karra</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Berlin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dinavitser</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Koren</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Berkovitch</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Safety of Mebendazole Use During Lactation: A Case Series Report.</article-title>
            <source>Drugs R D</source>
            <year>2016</year>
            <month>Sep</month>
            <volume>16</volume>
            <issue>3</issue>
            <fpage>251</fpage>
            <page-range>251-254</page-range>
            <pub-id pub-id-type="pmid">27623793</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24812.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dayan</surname>
                <given-names>AD</given-names>
              </name>
            </person-group>
            <article-title>Albendazole, mebendazole and praziquantel. Review of non-clinical toxicity and pharmacokinetics.</article-title>
            <source>Acta Trop</source>
            <year>2003</year>
            <month>May</month>
            <volume>86</volume>
            <issue>2-3</issue>
            <fpage>141</fpage>
            <page-range>141-59</page-range>
            <pub-id pub-id-type="pmid">12745134</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24812.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Keiser</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Utzinger</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of current drugs against soil-transmitted helminth infections: systematic review and meta-analysis.</article-title>
            <source>JAMA</source>
            <year>2008</year>
            <month>Apr</month>
            <day>23</day>
            <volume>299</volume>
            <issue>16</issue>
            <fpage>1937</fpage>
            <page-range>1937-48</page-range>
            <pub-id pub-id-type="pmid">18430913</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
